Resverlogix Corp.
TSX: RVX.TO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Toronto Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Donald J. McCaffrey
- Employees
- 19
- Headquarters
- Calgary, Canada
- IPO year
- 2004
- Market cap
- CA$31.6M
- Website
- https://www.resverlogix.com
Loading RVX…
Loading profile data…Frequently asked questions about RVX
What does Resverlogix Corp. (RVX.TO) do?
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chroni...
Where does RVX.TO trade?
Resverlogix Corp. (RVX.TO) trades on the Toronto Stock Exchange.
What sector is RVX.TO in?
Resverlogix Corp. (RVX.TO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Resverlogix Corp.?
Donald J. McCaffrey is the chief executive officer of Resverlogix Corp. (RVX.TO).
Where is Resverlogix Corp. headquartered?
Resverlogix Corp. is headquartered in Canada.
Does RVX.TO pay a dividend?
Resverlogix Corp. (RVX.TO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RVX.TO go public?
Resverlogix Corp. (RVX.TO) completed its initial public offering in 2004.